Navigation Links
New EBRI/Commonwealth Fund Research: Enrollment in Consumer-Driven Plans Remains Low, Survey Shows
Date:3/18/2008

More than 30% Enrolled in Consumer-Driven Plans Have Household Incomes Over $100,000 a Year

WASHINGTON, March 18 /PRNewswire-USNewswire/ -- Enrollment in consumer-driven and high-deductible health plans increased in 2007, but still makes up a small segment of the overall insurance market, according to the third EBRI/Commonwealth Fund Consumerism in Health Care Survey released today. Enrollment in consumer-driven plans with a tax-advantaged account was 2 percent of the privately insured adults in 2007. One in 10 insured adults had high-deductible health plans (HDHPs) without accounts. The survey also found the percentage of consumer-driven plan enrollees with high incomes (above $100,000) swelled in 2007.

Consumer-driven plans were introduced in 2001 with the goal of decreasing the number of uninsured, encouraging cost-consciousness among consumers, and increasing the amount of information on the cost and quality of providers. The plans have been controversial because of criticism they favor wealthy and healthy participants at the expense of those with lower incomes and poorer health status.

Results of the survey appear in the March 2008 EBRI Issue Brief, available at http://www.ebri.org, and on the Commonwealth Fund Web site, http://www.commonwealthfund.org. The EBRI/Commonwealth survey found differences in the types of people enrolled in the various health plans. Consumer-driven plan enrollees are in better health, are less likely to smoke, are more likely to exercise, and to be white, male, and higher-income. They are no more likely to have been uninsured prior to enrollment than adults in other plans. In terms of behavior, enrollees in consumer-driven plans are more cost-conscious about their health care than are people enrolled in more comprehensive plans, are less satisfied with their plans overall, and are more likely to
'/>"/>

SOURCE Employee Benefit Research Institute
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Experimental Biology 2008 Todays Research: Tomorrows Health, April 5-9
2. Manhattan Research: ePharma Consumer(R) Research and Advisory Service Now Available
3. Enrollment completed in 2 pivotal phase III studies of the investigational cancer drug vandetanib
4. Hyperion Therapeutics Announces Enrollment of First Patient in Phase 2 Clinical Trial in Patients With Hepatic Encephalopathy
5. New 2008 Health Plan Directory Features Year-End 2007 Enrollment Data and 4,600 Key Executives
6. Office of Administration Extends Retired State Employees Health Benefits Enrollment Period to March 21
7. Medicares Drug Program Enrollment Up, Costs Down
8. MedicareCRM(TM) Simplifies Annual Enrollment Period for Medicare Health Plans and Beneficiaries
9. Boosts in Managed Care Enrollment Seen Across The Board
10. Devax Announces Completion of Enrollment of DIVERGE Trial of Novel Drug- Eluting Stent System for Bifurcation Lesions
11. Blue Cross Stop Smoking Phone Coaching Enrollments Jumped in October

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)...ng medical device software engineering consulting ... certification. A relatively few medical device so...achieved ISO 13485 certification. Many medical dev... to other ISO standards as well. However, it is so...ing consulting firm to achieve the rigorous qualit...
(Date:12/2/2009)...Newswire/ -- A randomized, controlled study compar...nvasive treatment called percutaneous disc decompr...ile both treatments help patients in the short run...up to two years later. Results of the study, the f...al meeting of the Radiological Society of North Am...
(Date:12/2/2009)...asound of suspicious areas of the breast, includin...ternative to invasive biopsies for women under age...ented today at the annual meeting of the Radiologi...rming high-quality breast ultrasound, we can reduc...iagnostic procedures in young women," said senior ...
(Date:12/1/2009)...ate Christ Medical Center in Oak Lawn, Ill. has be...nter and the first for Chicago’s south and s... hospital’s plans today (December 1) by the ...rd. , Springfield, Ill. (...Lawn, Ill. has become the state’s newest kid...
(Date:12/1/2009)...c. 1 Reportlinker.com announces th...s catalogue: ,, The Future of Monoclonal Antib...hmarking, Product Pipeline and Deals Analysis ,...e-of-Monoclonal-Antibodies---Market-Forecasts-to-2...Deals-Analysis.html ,, Summary ,, The au...
Breaking Medicine News(10 mins):Health News:Medical Device Software Engineering Consulting firm Full Spectrum Software Earns ISO 13485 Certification 2Health News:Outpatient Disc Treatment Gives Long-Term Back Pain Relief 2Health News:Outpatient Disc Treatment Gives Long-Term Back Pain Relief 3Health News:Targeted breast ultrasound can reduce biopsies for women under 40 2Health News:State Approves Plans For Kidney Transplants At Advocate Christ Medical Center 2Health News:State Approves Plans For Kidney Transplants At Advocate Christ Medical Center 3Health News:Reportlinker Adds The Future of Monoclonal Antibodies - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 2Health News:Reportlinker Adds The Future of Monoclonal Antibodies - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 3Health News:Reportlinker Adds The Future of Monoclonal Antibodies - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 4Health News:Reportlinker Adds The Future of Monoclonal Antibodies - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 5Health News:Reportlinker Adds The Future of Monoclonal Antibodies - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 6Health News:Reportlinker Adds The Future of Monoclonal Antibodies - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 7Health News:Reportlinker Adds The Future of Monoclonal Antibodies - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 8Health News:Reportlinker Adds The Future of Monoclonal Antibodies - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 9Health News:Reportlinker Adds The Future of Monoclonal Antibodies - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 10Health News:Reportlinker Adds The Future of Monoclonal Antibodies - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 11Health News:Reportlinker Adds The Future of Monoclonal Antibodies - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 12Health News:Reportlinker Adds The Future of Monoclonal Antibodies - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 13
...ect of hormone replacement therapy may be inhibite...eroidal anti-inflammatory pain killer, report rese...f Pennsylvania. The researchers examined t...coronary heart disease and compared them with 7,00...
...ople another reason to quit smoking, by finding th...oping depression in comparison to those who never...kers who have quit have an elevated risk of depres... style and successful smoking cessation in long ru...
...that vegetarian diet reduces risk of colon cancer ...up as appetizer reduces food intake by about 20 pe...ife factors like choosing your diet regimen or ord...t to find out whether a vegetarian diet is associa...
...lthcare scenario has emerged a heartening developm...ated Paromomycin IM injection manufactured by the...fit drug firm, for inclusion in its Model List for...rasitic disease after malaria. It is a sy...
...ests using gene sequencing is able to help confirm...ns and patients the tools for much more accurate ...e a group of more than 40 inherited and potentiall...ucts that damage organs and tissues. The g...
...t men with chronic gum disease periodontitis, may ...ss of whether they smoke. Periodontitis is...a, though recent evidence suggests the involvement... Roswell Park Cancer Institute, Buffalo. A...
Other Medicine News:Health News:Regular Smokers are at the Risk of Developing Depression 2Health News:Vegetarian Diet Could Reduce Risk of Colon Cancer 2Health News:Vegetarian Diet Could Reduce Risk of Colon Cancer 3Health News:Vegetarian Diet Could Reduce Risk of Colon Cancer 4Health News:A Non-profit Drug Firms Injection to Fight Kala Azar Included in WHOs Model List 2Health News:A Non-profit Drug Firms Injection to Fight Kala Azar Included in WHOs Model List 3Health News:New DNA Tests Advances Treatment of Lysosomal Storage Diseases 2Health News:Men With Chronic Gum Disease at Higher Risk of Tongue Cancer 2
(Date:12/2/2009)..., EAST HANOVER, N.J., Dec. 2 Nova...te-breaking presentation on Tasigna® (nilotin...eukemia, demonstrate the strength of the company,s...ients. ,, The new data, at the 51st American S...sition, highlight the company,s current therapies ...
(Date:12/1/2009)...ULA, Calif., Dec. 1 Pati... PSTX) announced today that it has appointed Marc ...al Officer, Treasurer and Corporate Secretary, rep...2008. Prior to joining Patient Safety Technologie...f Financial Officer, Treasurer and Corporate Secre...
(Date:12/1/2009)...O BEACH, Calif., Dec. 1 Reproducti...ective Single Embryo Transfer (eSET) Encouragement...ents with good embryo quality and a good prognosis...ins by transferring a single embryo. ,, The big...ay is reducing the number of multiple pregnancies,...
Breaking Medicine Technology:Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 2Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 3Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 4Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 5Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 6Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 7Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 8Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 9Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 10Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 11Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 12Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 13Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 14Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 15Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 16Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 17Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 18Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 19Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 20Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 21Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 22Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 23Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 24Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 25Patient Safety Technologies, Inc. Appoints Marc L. Rose, CPA (PA), Chief Financial Officer 2Reproductive Partners Announces Elective Single Embryo Transfer (eSET) Encouragement Program 2Haemonetics Receives Favorable Ruling in Patent Lawsuit against Competitive Technology 12472 1Haemonetics Receives Favorable Ruling in Patent Lawsuit against Competitive Technology 12472 2Jefferson researchers identify critical marker of response to gemcitabine in pancreatic cancer 47918 1Jefferson researchers identify critical marker of response to gemcitabine in pancreatic cancer 47918 21 in 4 nursing home residents carry MRSA 47915 11 in 4 nursing home residents carry MRSA 47915 2
... Biotech (OMX Nordic: ACTI),has presented pre-clin...ongress on Inflammation (<a target="_blank" href=,...2007.dk ) held,in Copenhagen June 16-20*. , "The r... of,57-57 for the treatment of SLE and show the po...clinical trials are planned to be,initiated before...
...--Jun 19, 2007 - Geron,Corporation (Nasdaq: GERN) ...ble production, survival following engraftment and...rats was presented,today for GRNCM1, the company,s...c for heart failure, at the International,Society ...airns,Australia., The presentation was one of sev...
Other Medicine Technology:Active Biotech presents new pre-clinical data for the 57-57 project,at the 8th World Congress on Inflammation 2Research Documents Scalable Production, Survival Following,Engraftment and Positive Impact on Cardiac Function in Infarcted,Rats for Geron's Human Embryonic Stem Cell-Based Therapeutic for,Heart Failure 2Research Documents Scalable Production, Survival Following,Engraftment and Positive Impact on Cardiac Function in Infarcted,Rats for Geron's Human Embryonic Stem Cell-Based Therapeutic for,Heart Failure 3Research Documents Scalable Production, Survival Following,Engraftment and Positive Impact on Cardiac Function in Infarcted,Rats for Geron's Human Embryonic Stem Cell-Based Therapeutic for,Heart Failure 4Research Documents Scalable Production, Survival Following,Engraftment and Positive Impact on Cardiac Function in Infarcted,Rats for Geron's Human Embryonic Stem Cell-Based Therapeutic for,Heart Failure 5Research Documents Scalable Production, Survival Following,Engraftment and Positive Impact on Cardiac Function in Infarcted,Rats for Geron's Human Embryonic Stem Cell-Based Therapeutic for,Heart Failure 6
PulseOx 7500 Pulse Oximeter
Merlin Patient Care System
Safire Bi-directional Ablation Catheter
VASOVIEW® HemoPro™ Endoscopic Vessel Harvesting System
Medicine Products: